NNRTI Compounds for HIV Resistance and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs face challenges such as rapid viral mutation leading to resistant strains, high dosages, compliance issues, and side effects, necessitating the development of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced activity against mutant viruses and improved bioavailability.
Innovation Solution
Development of novel NNRTIs through computer-aided design using lead generation, property prediction, and Monte Carlo simulations, resulting in compounds with specific chemical structures that include heterocyclic groups and substituents to enhance performance against common RT mutants and facilitate synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-HIV drugs (NRTIs and PIs) are used to treat HIV infection, then viral replication is inhibited, but rapid viral mutation leads to resistant strains
Solution Approach 1:
The patent employs computer-aided design with Monte Carlo simulations using free-energy perturbation theory to systematically optimize molecular parameters of NNRTI compounds. This allows precise adjustment of chemical structures to enhance binding affinity to HIV reverse transcriptase while maintaining stability against mutation-induced resistance, directly addressing the reliability-versus-adaptability contradiction
Solution Approach 2:
The invention develops composite molecular structures combining heterocyclic groups with specific substituent patterns that create multi-functional drug molecules. These composite structures simultaneously achieve high potency against wild-type virus and improved resistance profiles against common mutants, resolving the contradiction between effective viral suppression and resistance development
2Reliability
If high dosages of anti-HIV drugs are administered, then viral replication is suppressed, but compliance difficulties and side effects increase
Solution Approach 1:
Through systematic optimization of pharmacokinetic parameters using free-energy perturbation theory, the patent achieves compounds with improved bioavailability and potency. This allows lower dosages to achieve the same therapeutic effect, directly improving patient compliance while maintaining reliable viral suppression
Solution Approach 2:
The patent replaces the mechanical approach of simply increasing drug dosage with a molecular design approach that optimizes drug-receptor binding affinity and pharmacokinetic properties. This substitution enables achieving better therapeutic outcomes at lower doses, reducing side effects and improving compliance
3Duration of action of stationary object
If long-term use of NRTIs and PIs is implemented, then chronic viral suppression is achieved, but morphologic and metabolic complications occur
Solution Approach 1:
The patent extracts the essential therapeutic function of anti-HIV drugs (inhibition of reverse transcriptase) while eliminating the harmful side effects associated with current NRTI and PI classes. The new NNRTI structures achieve viral suppression through a different mechanism that spares the metabolic pathways responsible for lipodystrophy and wasting complications
Solution Approach 2:
The invention introduces new chemical intermediaries (NNRTI compounds with specific heterocyclic structures) that mediate the inhibition of HIV reverse transcriptase without triggering the adverse metabolic responses associated with current therapies. These intermediary molecules provide the same therapeutic benefit through a different molecular pathway, reducing long-term complications
Data Source
AI summary
The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group; R2, R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.